How much funding has Castle Creek Biosciences raised?

Castle Creek Biosciences has raised $167.8M in total funding, most recently a Series D round.

Who are Castle Creek Biosciences's investors?

Castle Creek Biosciences's investors include Paragon Biosciences, Ligand Pharmaceuticals, Valor Equity Partners, Multiple investors, Fidelity Management.

Where is Castle Creek Biosciences headquartered?

Castle Creek Biosciences is headquartered in Exton, Pennsylvania, United States.

What industry is Castle Creek Biosciences in?

Castle Creek Biosciences operates in Biotech, Healthcare.

Castle Creek Biosciences

Cell and Gene Therapy Company

Exton, United States · $167.8M raised

Biotech

Healthcare

Headquarters: Exton, Pennsylvania
Business Model: B2B
Website: castlecreekbio.com

Total Funding: $167.8M
Last Round: $112.8M Series DMay 2022
Rounds: 4

About

Castle Creek Biosciences is a late-stage cell and gene therapy company developing re-dosable gene therapies for severe genetic skin diseases. Its lead program, D-Fi, is in a registrational Phase 3 trial for dystrophic epidermolysis bullosa (DEB). A portfolio company of Paragon Biosciences, it is headquartered in Exton, Pennsylvania.

Summary

Castle Creek Biosciences is a Biotech company based in Exton, United States. It has raised $167.8M in total across 4 rounds, most recently a $112.8M Series D round in May 2022. Investors include Paragon Biosciences, Ligand Pharmaceuticals and Valor Equity Partners.

LinkedIn X (Twitter)